Abstract
Worldwide, depression and bipolar disorder affect a large and growing number of people. However, current pharmacotherapy options remain limited. Despite adequate treatment, many patients continue to have subsyndromal symptoms, which predict relapse in bipolar illness and often result in functional impairments. Aspirin, a common nonsteroidal anti-inflammatory drug (NSAID), has purported beneficial effects on mood symptoms, showing protective effects against depression in early cohort studies. This systematic review thus aimed to investigate the role of aspirin in mood disorders. Using the keywords (aspirin or acetylsalicy* or asa) and (mood or depress* or bipolar or mania or suicid*), a comprehensive search of PubMed, EMBASE, Medline, PsycINFO, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group (CCDANTR), Clinicaltrials.gov and Google Scholar databases found 13,952 papers published in English between 1 January 1988 and 1 May 2019. A total of six clinical studies were reviewed. There were two randomized, placebo-controlled, double-blind trials and populations drawn from two main cohort studies (i.e., the Geelong Osteoporosis Study and the Osteoarthritis Initiative study). Using a random-effects model, the pooled hazard ratio of the three cohort studies was 0.624 (95% confidence interval: 0.0503 to 1.198, p = 0.033), supporting a reduced risk of depression with aspirin exposure. Overall, the dropout rates were low, and aspirin appears to be well-tolerated with minimal risk of affective switch. In terms of methodological quality, most studies had a generally low risk of bias. Low-dose aspirin (80 to 100 mg/day) is safe, well-tolerated and potentially efficacious for improving depressive symptoms in both unipolar and bipolar depression. Due to its ability to modulate neuroinflammation and central nervous system processes, aspirin may also have valuable neuroprotective and pro-cognitive effects that deserve further exploration. Further randomized, controlled trials involving the adjunctive use of aspirin should be encouraged to confirm its therapeutic benefits.
Highlights
Worldwide, mood disorders are a growing public health concern.Depression alone affects over 350 million people globally and accounts for approximately 7.5% of healthy years lost due to disability [1]
By using the following combinations of broad Major Exploded Subject Headings (MesH) terms or text words and, a comprehensive search of PubMed, EMBASE, Neurosis Group (CCDANTR), Clinicaltrials.gov and Google Scholar databases yielded 13,952 papers published in English between 1 January 1988 and 1 May 2019
Baseline and endpoint serum lithium concentrations and mood symptoms remained stable throughout the duration of the study
Summary
Depression alone affects over 350 million people globally and accounts for approximately 7.5% of healthy years lost due to disability [1]. A 2010 Global Burden of Disease Study reported that depression and bipolar disorder resulted in more than 85 million disability-adjusted life years [2], a startling human and economic cost. Depressive and bipolar disorders are both chronic conditions, and long-term maintenance treatment is necessary to prevent recurrence of symptoms, reduce residual symptoms, and maintain functioning [3,4]. The management of bipolar disorder remains a clinical challenge [7], with variable responses to treatment depending on the polarity of patients [8], and many patients continue to have subsyndromal symptoms. Subsyndromal symptoms in bipolar illness predict relapse and often result in functional impairments [9]. There is a need to research new and more-effective acute and maintenance therapies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
